Navigation Links
Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
Date:11/1/2010

e FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company is currently evaluating the FDA's comments in the CRL and anticipates meeting with the FDA before the end of the year to discuss the CRL.  For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Smile Train and ... to showcase their Virtual Surgery Simulator among leading global ... will take place in Washington, D.C. ... Performing Arts. "Smile Train is honored ... the talented community of innovators in health and medicine ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: ... Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... acquisition of both cultivation and dispensary medical marijuana licenses in ... the MOU, GBLX will acquire a 20% equity interest in ... GrowBLOX TM growing chambers, as well as all technology ...
(Date:7/25/2014)... -- Solanbridge Group Inc (OTC: SLNX) is pleased to announce ... and the Letter of Intent issued on July 11, ... Agreement. Charles R. Shirley , Managing ... Mr. David Pecoraro and Buzznbrewz.com join SLNX,s ... sector and developed a tremendous network of contacts who ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... May 19, 2011 Omeros Corporation ... it is advancing two of its product candidates ... meniscectomy and OMS302 for intra-ocular lens replacement surgery ... of these product candidates are added to standard ...
... (Nasdaq: ENMD ), a clinical-stage pharmaceutical company ... the presentation of clinical data for its Phase 2 ... data will be presented at the American Society of ... 3 - 7, 2011 in Chicago, Illinois. ...
Cached Medicine Technology:Omeros Announces Clinical Development Programs for OMS103HP and OMS302 2Omeros Announces Clinical Development Programs for OMS103HP and OMS302 3Omeros Announces Clinical Development Programs for OMS103HP and OMS302 4Omeros Announces Clinical Development Programs for OMS103HP and OMS302 5EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting 2EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting 3
(Date:7/28/2014)... TherapySites, the leading website and ... its affiliation with the Illinois Association for Marriage ... TherapySites to continue to extend their online marketing solutions ... , “There has been a fundamental shift in the ... 3 billion Internet users, it is so important to ...
(Date:7/28/2014)... According to the Heartburn No More PDF review ... will help people get rid of acid reflux ... about heartburn and acid reflux. In addition, inside this book, ... risk factors for reflux disease. , Vkool informs in ... of symptoms of reflux disease naturally without medications. The book ...
(Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... completed the exit of its investment in Loftware, Inc., ... Partners of Boston. Shore Points was the lead investor ... which the Company has become the leading international provider ... applications. , “Loftware has been a great investment for ...
(Date:7/27/2014)... Hyaluronic Acid can hold 1,000 times ... to the power of Hyaluronic Serums. , "Hyaluronic acid ... of Sublime Beauty®. "But like collagen, it diminishes with ... improves skin moisture-retention and radiance." , Hyaluronic acid ... healthy and beautiful look. Key Ingredients in the serum ...
(Date:7/27/2014)... hepatitis E virus (HEV) transmission by blood components indicates ... HEV in their plasma. The findings, published in ... components (eg, red cells, platelets, and fresh frozen plasma) ... , The study retrospectively screened 225 000 individual ... 2012 and Sept, 2013 for HEV RNA. 79 donors ...
Breaking Medicine News(10 mins):Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... that the brain is always alert even if there is ... they are listening out for a sound. ,Pierre ... national research institute. He studied the brain activity of 11patients ... Imaging. // It showed that they were actually listening ...
... leg pain and very pale skin can all be early ... ,Thousand’s of children's lives will be saved ... for parents, which could speed diagnosis and treatment. ... their child having a headache, stiff neck, sensitivity to light ...
... Professor Stuart J. Connolly and his team from McMaster ... JAMA that a combination of Antiarrhythmic drugs such as ... found to reduce the painful shocks in ventricular arrhythmia ... high voltage shocks which are used to treat fatal ...
... is lot of relaxation in weight reduction programs. This however cannot ... is to listen to one’s inner voice and constantly work towards ... voice starts piping up as you lie on the couch. "Go ... those potato chips," it urges., ,The voice is that ...
... led to researchers warning British tourists to keep away from ... into Britain. Despite these warnings of a possible spread of ... Association of British Travel Agents had reported that the tourist ... be not afraid of bird flu threat. The tour promoters ...
... shown that tomato juice prevented emphysema in mice exposed to ... disease. // ,The lung protective effect was attributed ... to be the first to link tomato consumption to emphysema ... 'We can't simply accept that these results go beyond the ...
Cached Medicine News:Health News:New warning signs for child meningitis 2Health News:Being Active In Winter Despite That Inner Urge 2
Lightweight & portable, compact station. Accurate and speedy measurement, auto-shot function, AI measuring function, focusing indicator....
... Medennium is an innovative device used ... duct, and conserve the eye's natural ... a range of punctum sizes. Made ... SmartPLUG adjusts to the exact shape ...
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Medicine Products: